William A Denny

List of Publications by Year
in descending order

158 papers	6,638 citations	57719 44 h-index	74108 75 g-index
162 all docs	162 docs citations	162 times ranked	6911 citing authors

#	Article	IF	Citations
1	Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2022, 229, 114059.	2.6	7
2	Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action. Molecules, 2022, 27, 880.	1.7	7
3	Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-Î±]pyrimidin-7-amine. Tetrahedron Letters, 2022, 90, 153611.	0.7	10
4	Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy. Pharmaceuticals, 2022, 15, 187.	1.7	17
5	Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation. Current Cancer Drug Targets, 2022, 22, 209-220.	0.8	6
6	Novel synthetic approach for accessing drugâ€“dye conjugates for targeted tumour therapy. Results in Chemistry, 2022, 4, 100343.	0.9	3
7	Tuberculosis Drug Discovery: Challenges and New Horizons. Journal of Medicinal Chemistry, 2022, 65, 7489-7531.	2.9	59
8	Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: InÂvitro and inÂvivo appraisal. European Journal of Medicinal Chemistry, 2021, 209, 112914.	2.6	17
9	Small-molecule CSF1R kinase inhibitors; review of patents 2015-present. Expert Opinion on Therapeutic Patents, 2021, 31, 107-117.	2.4	32
10	Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility. ACS Medicinal Chemistry Letters, 2021, 12, 275-281.	1.3	9
11	Inhibitors of F₁F₀-ATP synthase enzymes for the treatment of tuberculosis and cancer. Future Medicinal Chemistry, 2021, 13, 911-926.	1.1	5
12	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs. Oncology and Therapy, 2021, 9, 541-556.	1.0	11
13	The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors. Frontiers in Oncology, 2021, 11, 654921.	1.3	19
14	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	2.9	0
15	Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines. Bioorganic and Medicinal Chemistry Letters, 2021, 50, 128336.	1.0	7
16	Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation. Biomolecules, 2021, 11, 1671.	1.8	8
17	Inhibition of the Cytolytic Protein Perforin Prevents Rejection of Transplanted Bone Marrow Stem Cells in Vivo. Journal of Medicinal Chemistry, 2020, 63, 2229-2239.	2.9	7
18	Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology. Bioorganic and Medicinal Chemistry, 2020, 28, 115213.	1.4	25

#	Article	IF	Citations
19	Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry, 2020, 28, 115784.	1.4	16
20	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both inÂvitro and inÂvivo trypanocidal efficacy. European Journal of Medicinal Chemistry, 2020, 207, 112849.	2.6	13
21	Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity. Molecules, 2020, 25, 4888.	1.7	4
22	Structures and dynamics of DNA complexes of the desmethyl analog of the cytotoxin MLN944: Insights into activity when a methyl isn't futile. Journal of Molecular Recognition, 2020, 33, e2843.	1.1	2
23	PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127252.	1.0	14
24	Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria. Molecules, 2020, 25, 2431.	1.7	8
25	Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope. Bioconjugate Chemistry, 2020, 31, 1724-1739.	1.8	38
26	Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876â€"A Less Toxic and More Potent Analogue of Bedaquiline. Molecules, 2020, 25, 1423.	1.7	8
27	Structure-Activity Relationships for the Anaesthetic and Analgaesic Properties of Aromatic Ring-Substituted Ketamine Esters. Molecules, 2020, 25, 2950.	1.7	4
28	A New Selective Pharmacological Enhancer of the Orai1 Ca²⁺ Channel Reveals Roles for Orai1 in Smooth and Skeletal Muscle Functions. ACS Pharmacology and Translational Science, 2020, 3, 135-147.	2.5	27
29	Cyclic Tetrapeptides from Nature and Design: A Review of Synthetic Methodologies, Structure, and Function. Chemical Reviews, 2019, 119, 10318-10359.	23.0	37
30	The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2617-2621.	1.0	20
31	Boron in drug design: Recent advances in the development of new therapeutic agents. European Journal of Medicinal Chemistry, 2019, 179, 791-804.	2.6	154
32	Synthesis and Evaluation of Imidazo[1,2â€a]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3â€Kinase Inhibitors. Chemistry - an Asian Journal, 2019, 14, 1249-1261.	1.7	9
33	Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis. Annual Reports in Medicinal Chemistry, 2019, 52, 97-130.	0.5	4
34	Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline. Bioorganic and Medicinal Chemistry, 2019, 27, 1283-1291.	1.4	39
35	Ketamine esters and amides as short-acting anaesthetics: Structure-activity relationships for the side-chain. Bioorganic and Medicinal Chemistry, 2019, 27, 1226-1231.	1.4	9
36	3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel. Bioorganic and Medicinal Chemistry, 2019, 27, 1292-1307.	1.4	69

#	Article	IF	Citations
37	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2019, 27, 1529-1545.	1.4	12
38	Synthesis and Microtubuleâ€Destabilizing Activity of N â€Cyclopropylâ€4â€((3,4â€dihydroquinolinâ€1(2 H) Tj ETQq0 0 0 rgBT /Overloc	1.7	1
39	Development of (6R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2018, 61, 2329-2352.	2.9	42
40	Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorganic and Medicinal Chemistry, 2018, 26, 1797-1809.	1.4	63
41	Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 207-213.	1.0	22
42	An SAR study of hydroxy-trifluoromethylpyrazolines as inhibitors of Orai1-mediated store operated Ca2+ entry in MDA-MB-231 breast cancer cells using a convenient Fluorescence Imaging Plate Reader assay. Bioorganic and Medicinal Chemistry, 2018, 26, 3406-3413.	1.4	9
43	Investigation into Improving the Aqueous Solubility of the Thieno[2,3-b]pyridine Anti-Proliferative Agents. Molecules, 2018, 23, 145.	1.7	15
44	A mitochondria-selective near-infrared-emitting fluorescent dye for cellular imaging studies. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2013-2017.	1.0	6
45	Benzenesulphonamide inhibitors of the cytolytic protein perforin. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1050-1054.	1.0	12
46	Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. Journal of Controlled Release, 2017, 250, 62-76.	4.8	219
47	Homobivalent Conjugation Increases the Allosteric Effect of 9-aminoacridine at the Î±₁-Adrenergic Receptors. Molecular Pharmacology, 2017, 91, 135-144.	1.0	12
48	7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2017, 60, 4212-4233.	2.9	47
49	Novel pyrazolo[1,5- a]pyridines with improved aqueous solubility as p110Î±-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 187-190.	1.0	9
50	Substituted arylsulphonamides as inhibitors of perforin-mediated lysis. European Journal of Medicinal Chemistry, 2017, 137, 139-155.	2.6	7
51	6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2583-2589.	1.0	26
52	Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5190-5196.	1.0	49
53	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2017, 25, 5859-5874.	1.4	14
54	6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis. ACS Medicinal Chemistry Letters, 2017, 8, 1019-1024.	1.3	66

#	Article	IF	Citations
55	Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS Medicinal Chemistry Letters, 2017, 8, 1275-1280.	1.3	36
56	Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca 2+ entry in MDA-MB-231 breast cancer cells using a Fluorescence Imaging Plate Reader assay. Bioorganic and Medicinal Chemistry, 2017, 25, 440-449.	1.4	17
57	Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3KÎ±, in comparison to established pan PI3K inhibitors. Oncotarget, 2017, 8, 47725-47740.	0.8	11
58	Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. Journal of Medicinal Chemistry, 2016, 59, 8103-8124.	2.9	52
59	Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell International, 2016, 16, 18.	1.8	27
60	Synthesis and cytotoxicity of thieno[2,3-b]quinoline-2-carboxamide and cycloalkyl[b]thieno[3,2-e]pyridine-2-carboxamide derivatives. Bioorganic and Medicinal Chemistry, 2016, 24, 1142-1154.	1.4	19
61	Diarylthiophenes as inhibitors of the pore-forming protein perforin. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 355-360.	1.0	22
62	Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structureâ€“Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2016, 59, 2530-2550.	2.9	46
63	Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs. Anesthesia and Analgesia, 2015, 121, 925-933.	1.1	27
64	Synthesis and Structureâ€“Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry, 2015, 58, 3036-3059.	2.9	33
65	Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling. Bioorganic and Medicinal Chemistry, 2015, 23, 3796-3808.	1.4	9
66	Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3804-3809.	1.0	12
67	Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). Bioorganic and Medicinal Chemistry, 2014, 22, 1029-1039.	1.4	32
68	Human Î±1-adrenoceptor subtype selectivity of substituted homobivalent 4-aminoquinolines. Bioorganic and Medicinal Chemistry, 2014, 22, 5910-5916.	1.4	3
69	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. MedChemComm, 2014, 5, 41-46.	3.5	12
70	Fragmentation of the quinoxaline N-oxide bond to the Ë™OH radical upon one-electron bioreduction. Chemical Communications, 2014, 50, 13729-13731.	2.2	10
71	Comparison of hematin-targeting properties of pynacrine, an acridine analog of the benzonaphthyridine antimalarial pyronaridine. Acta Tropica, 2014, 140, 181-183.	0.9	4
72	Structureâ€“activity relationships for ketamine esters as short-acting anaesthetics. Bioorganic and Medicinal Chemistry, 2013, 21, 5098-5106.	1.4	18

#	Article	IF	Citations
73	Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin. Journal of Medicinal Chemistry, 2013, 56, 9542-9555.	2.9	30
74	Phosphoinositide 3-kinase Î± inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2013, 23, 789-799.	2.4	18
75	3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-Î²-Hydroxysteroid Dehydrogenase AKR1C3. Journal of Medicinal Chemistry, 2012, 55, 7746-7758.	2.9	33
76	Structureâ€“Activity Relationships for Amide-, Carbamate-, And Urea-Linked Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry, 2012, 55, 312-326.	2.9	53
77	Nitro seco Analogues of the Duocarmycins Containing Sulfonate Leaving Groups as Hypoxia-Activated Prodrugs for Cancer Therapy. Journal of Medicinal Chemistry, 2012, 55, 2780-2802.	2.9	27
78	Giving Anemia a Boost with Inhibitors of Prolyl Hydroxylase. Journal of Medicinal Chemistry, 2012, 55, 2943-2944.	2.9	12
79	Synthesis and Structureâ€“Activity Relationships of Varied Ether Linker Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry, 2011, 54, 6563-6585.	2.9	66
80	A new enantioselective approach to the core structure of hypoxia selective prodrugs related to the duocarmycins. Tetrahedron Letters, 2011, 52, 7000-7003.	0.7	6
81	The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy. Bioorganic and Medicinal Chemistry, 2011, 19, 5989-5998.	1.4	7
82	Selective Treatment of Hypoxic Tumor Cells In Vivo: Phosphate Preâ€Prodrugs of Nitro Analogues of the Duocarmycins. Angewandte Chemie - International Edition, 2011, 50, 2606-2609.	7.2	43
83	The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins. Bioorganic and Medicinal Chemistry, 2011, 19, 4851-4860.	1.4	10
84	Synthesis and Structureâ^'activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains. Journal of Medicinal Chemistry, 2010, 53, 855-866.	2.9	81
85	Hypoxic selectivity and solubilityâ€”investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy. Bioorganic and Medicinal Chemistry, 2010, 18, 4997-5006.	1.4	13
86	Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors. Clinical Cancer Research, 2010, 16, 4946-4957.	3.2	120
87	Synthesis and Structureâ^'Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry, 2010, 53, 8421-8439.	2.9	80
88	Characterization of Radicals Formed Following Enzymatic Reduction of 3-Substituted Analogues of the Hypoxia-Selective Cytotoxin 3-Amino-1,2,4-Benzotriazine 1,4-Dioxide (Tirapazamine). Journal of the American Chemical Society, 2010, 132, 2591-2599.	6.6	40
89	The nitroimidazooxazines (PA-824 and analogs): structureâ€“activity relationship and mechanistic studies. Future Medicinal Chemistry, 2010, 2, 1295-1304.	1.1	21
90	Synthesis and Structureâ^'Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry, 2010, 53, 282-294.	2.9	104

#	Article	IF	Citations
91	Spin Trapping of Radicals Other Than the ^{â€¢}OH Radical upon Reduction of the Anticancer Agent Tirapazamine by Cytochrome P₄₅₀ Reductase. Journal of the American Chemical Society, 2009, 131, 14220-14221.	6.6	55
92	Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitro seco-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents. Journal of Medicinal Chemistry, 2009, 52, 7258-7272.	2.9	47
93	Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry, 2009, 52, 637-645.	2.9	88
94	Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104. Clinical Cancer Research, 2007, 13, 3922-3932.	3.2	208
95	Synthesis of3H- and2H4-labelled versions of the hypoxia-activated pre-prodrug 2-[(2-bromoethyl)-2,4-dinitro-6- [[[2-(phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR-104). Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 7-12.	0.5	28
96	Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104. Tetrahedron, 2007, 63, 5470-5476.	1.0	18
97	Use of Three-Dimensional Tissue Cultures to Model Extravascular Transport and Predict In Vivo Activity of Hypoxia-Targeted Anticancer Drugs. Journal of the National Cancer Institute, 2006, 98, 1118-1128.	3.0	139
98	Hydrogen-bonded networks from novel platinum(ii) dimers. CrystEngComm, 2005, 7, 701.	1.3	3
99	Design, Synthesis, and in Vitro Evaluation of Dipeptide-Based Antibody Minor Groove Binder Conjugates. Journal of Medicinal Chemistry, 2005, 48, 1344-1358.	2.9	85
100	Hypoxia-activated anticancer drugs. Expert Opinion on Therapeutic Patents, 2005, 15, 635-646.	2.4	16
101	Oxidation of 2-Deoxyribose by Benzotriazinyl Radicals of Antitumor 3-Amino-1,2,4-benzotriazine 1,4-Dioxides. Journal of the American Chemical Society, 2004, 126, 7865-7874.	6.6	37
102	Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opinion on Emerging Drugs, 2004, 9, 105-133.	1.0	13
103	Tumor-activated Prodrugsâ€"A New Approach to Cancer Therapy. Cancer Investigation, 2004, 22, 604-619.	0.6	143
104	Emerging DNA topisomerase inhibitors as anticancer drugs. Expert Opinion on Emerging Drugs, 2004, 9, 105-133.	1.0	40
105	Edotecarin. IDrugs: the Investigational Drugs Journal, 2004, 7, 173-7.	0.7	3
106	Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochemical Pharmacology, 2003, 65, 1807-1815.	2.0	31
107	Activation of 3-Amino-1,2,4-benzotriazine 1,4-Dioxide Antitumor Agents to Oxidizing Species Following Their One-Electron Reduction. Journal of the American Chemical Society, 2003, 125, 748-756.	6.6	114
108	Structureâ"Activity Relationships for 4-Nitrobenzyl Carbamates of 5-Aminobenz[e]indoline Minor Groove Alkylating Agents as Prodrugs for GDEPT in Conjunction withE.coliNitroreductase. Journal of Medicinal Chemistry, 2003, 46, 2456-2466.	2.9	35

#	Article	IF	Citations
109	Synthesis and Evaluation of Nitroheterocyclic Carbamate Prodrugs for Use with Nitroreductase-Mediated Gene-Directed Enzyme Prodrug Therapy. Journal of Medicinal Chemistry, 2003, 46, 5533-5545.	2.9	59
110	Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Research, 2003, 63, 5970-7.	0.4	77
111	Acridine Derivatives as Chemotherapeutic Agents. Current Medicinal Chemistry, 2002, 9, 1655-65.	1.2	268
112	Irreversible inhibitors of the erbB family of protein tyrosine kinases. , 2002, 93, 253-261.		33
113	American Association for Cancer Research - 93rd Annual Meeting. Investigational kinase inhibitors. 6-10 April 2002, San Francisco, CA, USA. IDrugs: the Investigational Drugs Journal, 2002, 5, 416-21.	0.7	0
114	Synthesis and Cytotoxic Activity of 7-Oxo-7H-dibenz[f,ij]isoquinoline and 7-Oxo-7H-benzo[e]perimidine Derivatives. Journal of Medicinal Chemistry, 2001, 44, 2004-2014.	2.9	86
115	Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine. Journal of Medicinal Chemistry, 2001, 44, 3511-3522.	2.9	48
116	Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents. Tetrahedron, 2000, 56, 645-657.	1.0	34
117	Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:Â 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. Journal of Medicinal Chemistry, 2000, 43, 1380-1397.	2.9	261
118	Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamatesâ€Šâ€. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 1601-1608.	1.3	21
119	Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1Hâ€Š)-ones via diazotization of 3-aryl-1,6-naphthyridine-2,7-diamines. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 1843-1852.	1.3	7
120	Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands. Dalton Transactions RSC, 2000, , 925-932.	2.3	71
121	DNA minor groove alkylating agents. Expert Opinion on Therapeutic Patents, 2000, 10, 459-474.	2.4	12
122	Guanine Specific Binding at a DNA Junction Formed by d[CG(5-BrU)ACG]2 with a Topoisomerase Poison in the Presence of Co2+ Ions,. Biochemistry, 2000, 39, 15055-15061.	1.2	23
123	Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opinion on Investigational Drugs, 2000, 9, 2889-2901.	1.9	93
124	A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2237-2242.	1.0	52
125	Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 1999, 42, 1803-1815.	2.9	173
126	Cytotoxicity and DNA Interaction of the Enantiomers of 6-Amino-3-(chloromethyl)-1-[(5,6,7-trimethoxyindol-2-yl)carbonyl]indoline (Amino-seco-CI-TMI). Chemical Research in Toxicology, 1999, 12, 700-706.	1.7	13

#	Article	IF	Citations
127	Structureâ^'Activity Relationships for Substituted Bis(acridine-4-carboxamides):â€‰ A New Class of Anticancer Agents. Journal of Medicinal Chemistry, 1999, 42, 2383-2393.	2.9	145
128	Crystal Structure of the Topoisomerase II Poison 9-Amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide Bound to the DNA Hexanucleotide d(CGTACG)2â€. Biochemistry, 1999, 38, 9221-9233.	1.2	88
129	DNA Adducts of 9-Anilinoacridine Mustards:â€‰ Characterization by NMR. Chemical Research in Toxicology, 1999, 12, 1166-1172.	1.7	15
130	Synthesis and Cytotoxicity of Amino-seco-DSA:Â An Amino Analogue of the DNA Alkylating Agent Duocarmycin SA. Journal of Organic Chemistry, 1999, 64, 5946-5953.	1.7	33
131	Synthesis and Cytotoxicity of 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (Amino-seco-CBI-TMI) and Related 5-Alkylamino Analogues:â€‰ New DNA Minor Groove Alkylating Agents. Journal of Organic Chemistry, 1998, 63, 9414-9420.	1.7	50
132	DNA-Directed Alkylating Agents. 7. Synthesis, DNA Interaction, and Antitumor Activity of Bis(hydroxymethyl)- and Bis(carbamate)-Substituted Pyrrolizines and Imidazoles. Journal of Medicinal Chemistry, 1998, 41, 4744-4754.	2.9	72
133	Topoisomerase Targeted Agents â€“ Chemistry to Chemotherapy. Expert Opinion on Investigational Drugs, 1998, 7, 1727-1730.	1.9	0
134	The 134th British Pharmaceutical Conference. Expert Opinion on Investigational Drugs, 1997, 6, 1553-1554.	1.9	0
135	Minor groove binding of a bis-quaternary ammonium compound: the crystal structure of SN 7167 bound to d(CGCGAATTCGCG)2. Nucleic Acids Research, 1997, 25, 4072-4078.	6.5	14
136	Dual topoisomerase I/II poisons as anticancer drugs. Expert Opinion on Investigational Drugs, 1997, 6, 1845-1851.	1.9	36
137	Structureâ^'Activity Relationships for Acridine-Substituted Analogues of the Mixed Topoisomerase I/II Inhibitor N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 1997, 40, 1919-1929.	2.9	70
138	Tyrosine Kinase Inhibitors. 6. Structureâ^'Activity Relationships amongN- and 3-Substituted 2,2â€˜-Diselenobis(1H-indoles) for Inhibition of Protein Tyrosine Kinases and Comparativein Vitroandin VivoStudies against Selected Sulfur Congeners. Journal of Medicinal Chemistry, 1997, 40, 413-426.	2.9	62
139	Hypoxia-Selective Antitumor Agents. 14. Synthesis and Hypoxic Cell Cytotoxicity of Regioisomers of the Hypoxia-Selective Cytotoxin 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Journal of Medicinal Chemistry, 1996, 39, 2518-2528.	2.9	40
140	Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 1996, 39, 918-928.	2.9	162
141	Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structureâ^'Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 1996, 39, 267-276.	2.9	304
142	Hypoxia-Selective Antitumor Agents. 12. Nitrobenzyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine. Journal of Medicinal Chemistry, 1996, 39, 1084-1094.	2.9	41
143	Unexpected rearrangement products from animations of 5â€bromoâ€2â€nitrothiazole. Journal of Heterocyclic Chemistry, 1996, 33, 1191-1194.	1.4	5
144	STRUCTURE-ACTIVITY RELATIONSHIPS FOR 4-ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITRO. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 424-427.	0.9	30

#	Article	IF	Citations
145	Radiolytic studies of the reductive cyclization of 2-nitroarylamides: Cyclization via hydroxylamine intermediates. Journal of Physical Organic Chemistry, 1995, 8, 587-596.	0.9	8
146	Mono-, bis- and tetra-acridine ligands: Synthesis, X-ray structural determination and dynamic fluorescence microscopic studies on the modification of the higher order structure of DNA. Journal of Physical Organic Chemistry, 1995, 8, 597-604.	0.9	7
147	Meeting Highlights: Palo Alto Institute of Molecular Medicine 31 January - 1 February 1994, Mountain View, California, USA: Nucleic acid binding drugs. Expert Opinion on Investigational Drugs, 1994, 3, 399-401.	1.9	0
148	Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. Journal of Medicinal Chemistry, 1992, 35, 3214-3222.	2.9	69
149	Surface-enhanced Raman spectroscopic study of amsacrine and amsacrine-DNA interactions. Journal of Raman Spectroscopy, 1992, 23, 341-345.	1.2	10
150	Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. Journal of Medicinal Chemistry, 1990, 33, 112-121.	2.9	99
151	Quantitative Structureâ€"Activity Relationships for the Cytotoxicity of Substituted Aniline Mustards in Tissue Culture. ACS Symposium Series, 1989, , 291-300.	0.5	1
152	Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. Journal of Medicinal Chemistry, 1989, 32, 793-799.	2.9	118
153	Alkyl-linked diquinolines are monofunctional AT-selective DNA-intercalating agents. FEBS Letters, 1988, 228, 235-240.	1.3	7
154	Crystallographic and Molecular Mechanics Calculations on the Anti-Tumor Drugs N-[(2-Dimethylamino)Ethyl]-and N-[(2-Dimethyl-Amino)Butyl]-9-Aminoacridine-4-Carboxamides and their Dications: Implications for Models of DNA-Binding. Journal of Biomolecular Structure and Dynamics, 1987, 5, 145-158.	2.0	13
155	The Synthesis of 9-Oxo-9, 10-Dihydroacridine-4-carboxylic Acidsviathe Jourdan-Ullmann Reaction of Anthranilic Acids and Methyl 2-Iodobenzoates. Synthetic Communications, 1987, 17, 309-317.	1.1	11
156	Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. Journal of Medicinal Chemistry, 1986, 29, 879-887.	2.9	129
157	Nitroacridines with selective toxicity towards hypoxic mammalian cells: Synthesis and stability of tritiated derivatives. Journal of Labelled Compounds and Radiopharmaceuticals, 1985, 22, 995-1005.	0.5	9
158	Acridine-4-Carboxamides and the Concept of Minimal DNA Intercalators. , 0, , 482-502.		3